Dec. 28, 2020
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA
Press Releases
-
News
-
Business
Dec. 21, 2020WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer -
News
Dec. 14, 2020GMP Inspection Completed by ANVISA at WuXi Biologics DS facility -
Collaboration
Dec. 10, 2020Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer -
Collaboration
Dec. 02, 2020Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation -
News
Nov. 20, 2020WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou -
Collaboration
Nov. 09, 2020WuXi Biologics and AC Immune Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development -
Collaboration
Oct. 29, 2020WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa -
News
Oct. 08, 2020WuXi Biologics Unveils New Process Development and Testing Facility in King of Prussia, Pennsylvania
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?